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Obesity is associated with increased blood pressure
(BP), which in turn increases the risk of cardiovascu-
lar diseases. We found that the increase in leptin
levels seen in diet-induced obesity (DIO) drives an
increase in BP in rodents, an effect that was not
seen in animals deficient in leptin or leptin receptors
(LepR). Furthermore, humans with loss-of-function
mutations in leptin and the LepR have low BP
despite severe obesity. Leptin’s effects on BP are
mediated by neuronal circuits in the dorsomedial hy-
pothalamus (DMH), as blocking leptin with a specific
antibody, antagonist, or inhibition of the activity of
LepR-expressing neurons in the DMH caused a
rapid reduction of BP in DIO mice, independent of
changes in weight. Re-expression of LepRs in the
DMH of DIO LepR-deficient mice caused an increase
in BP. These studies demonstrate that leptin cou-
ples changes in weight to changes in BP in mamma-
lian species.INTRODUCTION
Obesity increases the risk for hypertension and is a major driver
of morbidity and mortality due to cardiovascular diseases (Du-1404 Cell 159, 1404–1416, December 4, 2014 ª2014 The Authorsstan, 1983; Poirier et al., 2006). Studies in rodents with diet-
induced obesity (DIO) suggest that increased sympathetic nerve
activity (SNA) is an important mediator of obesity-induced hyper-
tension as a and b adrenergic receptor antagonists and renal
denervation significantly blunt the rise in blood pressure (BP)
associated with weight gain (Carlyle et al., 2002; Esler et al.,
2006; Kassab et al., 1995). However, the precise molecular
and neural mechanisms that link changes in weight with changes
in BP have not been fully elucidated.
Circulating concentrations of the adipocyte-derived hormone
leptin increase in proportion to adipose tissue mass and fall with
weight loss (Considine et al., 1996; Maffei et al., 1995). As such,
we hypothesized that leptin may be involved in coupling
changes in body weight (BW) to changes in BP. Leptin regulates
energy homeostasis by acting on hypothalamic neuronal cir-
cuits expressing the signaling isoform of the leptin receptor
(LepR) to reduce calorie intake and increase energy expenditure
(Halaas et al., 1997; Harris et al., 1998; Maffei et al., 1995; Zhang
et al., 1994). Leptin can increase SNA, leading to increases
in BP and heart rate (HR) (Haynes, 2000; Mark et al., 1999). In
the arcuate nucleus of the hypothalamus (ARH), leptin stimu-
lates the expression of pro-opiomelanocortin (POMC) and
increases the activity of POMC neurons, which release the
POMC peptides (a, b, and g melanocyte-stimulating hormones
[MSHs]) that act on melanocortin 4-receptor (MC4R)-expressing
neurons in the paraventricular nucleus of the hypothalamus
(PVH) and other brain regions to increase SNA (Cone, 2005;
Cowley et al., 1999, 2001; Haynes et al., 1999). However,
Figure 1. Temporal Relationship between Changes in Weight Gain, Plasma Leptin Concentrations, and Blood Pressure
(A) Body weight (g), of mice from 4 weeks of age ad libitum fed either a high-calorie diet (DIO mice) or chow diet (lean mice) for 20 weeks. Following this 20 week
period, DIO mice were switched to chow diet for 4 weeks; n = 3–7.
(B–E) (B) Plasma leptin concentration (ng/ml), (C) heart rate BPM (beats per min), (D) SBP, and (E) DBP (mmHg) at 2 week intervals, beginning at baseline (4-week-
old mice). Following this baseline period, mice were fed a high-calorie diet (DIO) or chow diet (lean) for 20 weeks ad libitum. After 20 weeks of HFD in DIO mice,
these mice were switched to chow diet for 4 weeks. n = 3–18.
Values mean ± SEM; two-way AVOVA, Bonferroni post hoc test. *p < 0.05, **p < 0.01, and **p < 0.001.POMC neurons become unresponsive to leptin in obesity, and
leptin can act independently of MC4R signaling (Enriori et al.,
2011; Patterson et al., 2011; Scott et al., 2009). Therefore,
leptin’s effects beyond the melanocortin circuits need to be
investigated. The dorsomedial hypothalamus (DMH) is critical
for leptin’s ability to regulate brown adipose tissue (BAT) tem-
perature and the cardiovascular system (Enriori et al., 2011;
Fontes et al., 2001; Horiuchi et al., 2006; Marsh et al., 2003;
Rezai-Zadeh et al., 2014).
Here, we investigated the development of obesity-induced
hypertension. We demonstrate that, in DIO mice, increasing
levels of leptin directly lead to an increase in HR and BP and
that blocking the actions of leptin reverses these effects via neu-
ral circuits originating in the DMH. Furthermore, humans with
loss-of-function mutations in leptin and its receptor have normal
BP despite severe obesity, suggesting that these mechanisms
are likely to be preserved in humans.RESULTS
Weight Gain Increases Leptin Levels, Heart Rate, and
Blood Pressure
The temporal association between weight gain, changes in
circulating leptin levels, HR, and BP were first examined. Four-
week-old C57Bl/6J mice on a chow diet were implanted with
radiotelemetric BP probes; baseline measurements were re-
corded at 6 weeks. As BW increased (Figure 1A), plasma leptin
levels also progressively increased (Figure 1B). After 4 weeks
of HFD, HR became significantly elevated (Figure 1C) and re-
mained elevated throughout the 20 week recording period
compared to chow fed mice. Systolic blood pressure (SBP)
and diastolic blood pressure (DBP) were significantly elevated
after 12 weeks of HFD (Figures 1D and 1E), subsequent to the
rise in plasma leptin concentration. When HFD-fedmice were re-
turned to a chow diet following 20 weeks of HFD feeding, miceCell 159, 1404–1416, December 4, 2014 ª2014 The Authors 1405
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lost 3.9 g in the first week, 3.9 g in the second week, 3.4 g in the
third week, and 0.4 g in the fourth week (Figure 1A). DBP reduced
after 1 week (Figure 1E), and SBP (Figure 1D) and HR (Figure 1C)
reduced after 2 weeks of chow feeding. These findings suggest
that leptin appears to increase before HR and BP increases in
DIO, effects that are reversed with weight loss.
Leptin Signaling Is Required for Obesity-Induced
Increases in Blood Pressure
We examined whether the effects seen in DIO mice are depen-
dent upon leptin signaling, using mice lacking leptin (ob/ob) or
the LepR (db/db). HFD-fed ob/ob and db/db mice were signifi-
cantly (p < 0.001) heavier than HFD-fed DIO and chow-fed
lean, ob/ob, and db/db mice (Figure 2A). Despite the increased
severity of obesity in the ob/ob and db/db mice, only DIO mice
exhibited elevated HR, SBP, and DBP (Figures 2B–2G), demon-
strating that increased BW alone is not the cause of the increase
in BP in obesity. There was a greater difference in HR and BP be-
tween DIO mice to other mice during the dark period compared
to the light period (Figures S1A–S1C available online). The in-
crease in cardiovascular parameters in DIO mice was not due
to increased activity (Figures S1D and S1E).
Strong correlations were found in C57Bl/6J mice between
plasma leptin concentration and HR (Figure 2H), SBP (Figure 2I),
and DBP (Figure 2J). No correlation was found between plasma
insulin concentration and HR, SBP, or DBP (Figures S1G–S1I).
To examine the direct effect of leptin on BP, leptin-deficient
ob/obmice were treated for 11 days with either leptin or vehicle.
After 11 days of treatment, the average plasma leptin concentra-Figure 2. Leptin Signaling Is Required for the Obesity-Induced Increas
(A) Bodyweight (g) of mice fed 20weeks a high-calorie (DIO, ob/ob, and db/dbmic
+++p < 0.001 versus ob/ob HFD fed, ###p < 0.001 versus db/db HFD (lean, n = 1
(B) Average heart rate (BPM) over a 24 hr period of mice fed a high-calorie (DIOmic
20 weeks (lean, n = 14; DIO, n = 37; ob/ob, n = 8; db/db, n = 3; ob/ob, HFD = 3;
(C) Heart rate (BPM) over a 24 hr period in mice fed a chow diet (lean mice), HFD-
mice. Measurements at 20 weeks are presented (lean, n = 14; DIO, n = 37; ob/o
(D) Average SBP (mmHg) over a 24 hr period of mice fed a high-calorie (DIO mi
20 weeks (lean, n = 14; DIO, n = 37; ob/ob, n = 8; db/db, n = 3; ob/ob, HFD = 3;
(E) SBP (mmHg) over a 24 hr period in mice fed a chow diet (lean mice), HFD-fed D
for 20 weeks (lean, n = 14; DIO, n = 37; ob/ob, n = 8; db/db, n = 3; ob/ob, HFD =
(F) Average DBP (mmHg) over a 24 hr period of mice fed a high-calorie (DIO mi
20 weeks (lean, n = 14; DIO, n = 37; ob/ob, n = 8; db/db, n = 3; ob/ob, HFD = 3;
(G) DBP (mmHg) over a 24 hr period in mice fed a chow diet (leanmice), HFD-fed D
(lean, n = 14; DIO, n = 37; ob/ob, n = 8; db/db, n = 3; ob/ob, HFD = 3; db/db, HF
(H) Plasma leptin (ng/ml) correlates with heart rate (BPM). Linear regression, r2 =
(I) Plasma leptin (ng/ml) correlates with SBP (mmHg). Linear regression, r2 = 0.62
(J) Plasma leptin (ng/ml) correlates with DBP. Linear regression, r2 = 0.5883; p <
(K) Exogenous leptin administration into ob/ob mice increased heart rate. Vehic
produced no change. Two-way ANOVA, Bonferroni post hoc test. n = 3–8.
(L) Average heart rate (BPM) over 11 day treatment period of leptin-treated ob/ob
mice. One-way ANOVA, Bonferroni post hoc test, paired t test between leptin-tr
(M) Exogenous leptin administration into ob/ob mice, increased SBP (mmHg).
produced no change. Values represent mean ± SEM. Two-way ANOVA, Bonferr
(N) Average SBP (mmHg) over 11 day treatment period of leptin-treated ob/ob m
ments. One-way ANOVA, Bonferroni post hoc test, paired t test between leptin-
(O) Exogenous leptin administration into ob/obmice increased diastolic BP (DBP)
mice produced no change. Two-way ANOVA, Bonferroni post hoc test. n = 3–8.
(P) Average DBP (mmHg) over 11 day treatment period of leptin-treated ob/ob m
One-way ANOVA, paired t test between leptin-treated ob/ob mice and ob/ob ba
Values represent mean ± SEM, one-way AVOVA, Bonferroni post hoc test, unlesstion of ob/ob mice treated with leptin was 27.7 ± 2.9 ng/ml
compared to 36.3 ± 4.9 ng/ml in DIO mice and 6.6 ± 1.1 ng/ml
in lean mice (Figure S1F). Exogenous leptin treatment in ob/ob
mice progressively decreased BW (Figure S1M) and food intake
(FI) (Figure S1N) compared to leptin-treated db/db mice and
vehicle-treated ob/ob mice. Despite this decrease in BW, leptin
treatment increased HR (Figures 2K and 2L) and SBP (Figures
2M and 2N) in leptin-treated ob/ob mice compared to leptin-
treated db/db mice and vehicle-treated ob/ob mice. DBP also
increased in ob/ob leptin-treated mice, however, not to the
same extent as SBP (Figures 2O and 2P). The magnitude of
the increase in HR and BP in leptin-treated ob/ob mice
decreased with time, coincident with their substantial reduction
in BW. The 24 hr circadian rhythm of HR (Figure S2J), SBP (Fig-
ure S2K), and DBP (Figure S1L) of leptin-treated ob/obmice was
increased toward the baseline recordings of DIO mice. These
changes were not explained by increased activity (Figure S1O).
Inhibition of Leptin Signaling Reduces Elevated BP
Peripheral administration of a leptin antibody into DIO mice for
5 days caused a significant reduction in HR (Figure 3A), SBP (Fig-
ure 3B), and DBP (Figure 3C), although no change in BW was
observed (Figure 3D). Central administration of a leptin receptor
antagonist (LRA) into the lateral ventricle (LV) of hypertensive DIO
mice over a 7 day period significantly reduced the elevated HR
(p < 0.001; Figure 3E). By the seventh day of LRA treatment,
HR was comparable to the average HR of lean animals (Figures
3F and S2A). Systolic BP also progressively decreased when
DIO mice were treated with the LRA, and by day 5 of LRAes in BP
e) or chow (lean ob/ob and db/dbmice) diet ad libitum, ***p < 0.001 versus lean,
4; DIO, n = 37; ob/ob, n = 8; db/db, n = 3; ob/ob, HFD = 3; db/db, HFD = 5).
e) or chow (leanmice) diet, ob/obmice and db/dbmice fed a chow diet for over
db/db, HFD = 5).
fed DIO mice, chow-fed ob/ob and db/dbmice, and HFD-fed ob/ob and db/db
b, n = 8; db/db, n = 3; ob/ob, HFD = 3; db/db, HFD = 5).
ce) or chow (lean mice) diet, ob/ob mice and db/db mice fed a chow diet for
db/db, HFD = 5).
IOmice, chow-fed ob/ob and db/dbmice, and HFD-fed ob/ob and db/dbmice
3; db/db, HFD = 5).
ce) or chow (lean mice) diet, ob/ob mice and db/db mice fed a chow diet for
db/db, HFD = 5).
IOmice, chow-fed ob/ob and db/dbmice, and HFD-fed ob/ob and db/dbmice
D = 5).
0.5855; p < 0.001; n = 24.
05; p < 0.001; n = 24.
0.001; n = 24.
le (Veh) treatment into ob/ob mice and leptin administration into db/db mice
mice, compared to the baseline HR of ob/obmice, the baseline of DIO and lean
eated ob/ob mice and ob/ob baseline, n = 8–37.
Vehicle treatment into ob/ob mice and leptin administration into db/db mice
oni post hoc test. n = 3–8.
ice compared to ob/ob baseline SBP, DIO, and lean baseline SBP measure-
treated ob/ob mice and ob/ob baseline. n = 8–37.
(mmHg). Vehicle treatment into ob/obmice and leptin administration into db/db
ice compared to ob/ob baseline DBP, DIO baseline DBP, and lean mice DBP.
seline. n = 8–37.
specifically stated. *p < 0.05, **p < 0.01, and ***p < 0.001. See also Figure S1.
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treatment, SBP was significantly (p % 0.05) decreased com-
pared to vehicle-treated DIO mice (Figure 3G). By the seventh
day of LRA treatment, SBP was significantly (p < 0.05) lower
compared to the SBP at baseline in DIOmice and was compara-
ble to the baseline SBP of lean mice (Figures 3H and S2B). SBP
increased after LRA treatment ended. DBP also decreased
throughout the LRA treatment period (Figures 3I, 3J, and S2C).
These changes were seen despite the absence of a significant
change in FI (Figure 3K), indicating that these changes are medi-
ated by blocking the effects of leptin signaling rather than
through changes in FI and BW.
Leptin Modulates BP via Neural Circuits in the
Dorsomedial Hypothalamus
To determine whether leptin’s effects on BP and HR were medi-
ated by neurons in the DMH, the LRA was injected directly into
the DMH of hypertensive DIO mice daily over 7 days. LRA treat-
ment in the DMH decreased HR (Figures 4A, 4B, and S3A) and
SBP (Figures 4C, 4D, and S3B) by day 7 of treatment. No signif-
icant change in DBP (Figures 4E, 4F, and S3C) was observed.
Furthermore, injection of an AAV expressing a short hairpin
RNA directed against the LepR (Hommel et al., 2006) in the
DMH of DIO mice led to a sustained decrease in SBP (Figures
4G, 4H, and S3D) after 4 weeks. Utilizing mice in which the
LepR is flanked by loxP sites and can be deleted by an AAV
Cre, HFD for 20 weeks induced increased SBP at baseline,
whereas AAV Cre administration into the DMH (hence deleting
the LepR in only the DMH regions) decreased SBP (Figure 4I).
Additionally, we examined the effects of reactivation of the
LepR by injection of an AAV-expressing Cre recombinase into
the DMH of normotensive morbidly obese LepR null mice (ex-
pressing a loxP flanked STOP codon in front of the LepR, called
LepR transcriptional blocker or ‘‘LepR TB’’ mice; Berglund et al.,
2012). Both HR (Figure 4J) and SBP (Figure 4K) increased rapidly
after LepR expression was reactivated in just the DMH of obese
LepR-deficient mice.
Depolarization of DMH LepR-Expressing Neurons
To determine the electrophysiological effect of leptin on DMH
neurons, we recorded the electrical activity of neurons ex-
pressing LepR in LepR-Cre-YFP mice (Leshan et al., 2012).
Whole-cell recordings were obtained from 34 DMH neurons ex-
pressing LepR. Application of 100 nM leptin induced membraneFigure 3. Blockade of Leptin Actions in DIO Mice Reduces Elevated B
(A–C) (A) Percentage change in HR, (B) SBP, and (C) DBP over a 5 day treatment pe
(D) Percentage daily change in body weight of DIO mice before and during 5 da
Two-way ANOVA, Bonferroni post hoc test. n = 4–8.
(E) Daily change in HR (BPM) in DIO mice treated LV with aCSF or leptin recepto
(F) Total 24hr HR(BPM) after 7 days of LRA treatment in DIO mice compared to l
t test. n = 6–37.
(G) Daily change in SBP (mmHg) from baseline in DIO mice treated in the LV with
(H) Total 24 hr SBP (mmHg) after 7 days of LRA treatment in DIO mice compared
unpaired t test. n = 6–37.
(I) Daily change in DBP (mmHg) in DIO mice treated with LVaCSF or LRA. Two-w
(J) Total 24 hr DBP (mmHg) after 7 days of LRA in DIOmice compared to the baseli
unpaired t test. n = 6–37.
(K) Average food intake over the 7 day treatment period of LVaCSF (control) or L
Values represent mean ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001. See alsodepolarization and/or an increase in spontaneous action poten-
tial firing rate in 38.2% of recorded neurons (Figure 5A). Leptin
induced a mean peak amplitude depolarization of 4.9 ± 1.0 mV
from a mean resting potential of 49.9 ± 3.1 mV to a new
steady-state membrane potential of 45.0 ± 2.7 mV (p =
0.0004). Leptin-induced excitation was associated with an in-
crease in firing rate from a mean control basal level of 0.48 ±
0.28 Hz to 0.64 ± 0.34 Hz in the presence of leptin (n = 5),
effects that were at least in part reversible after washout of
leptin (p = 0.59). In two neurons, leptin induced sub- and supra-
threshold oscillations in membrane potential (Figure S4A).
Voltage-current relations, generated in response to a rangeof de-
polarizing and hyperpolarizing rectangular-wave current pulses
(150 to +100 pA, 1,000 ms duration) revealed that leptin-
induced excitation was principally associated with a trend for a
decrease (p = 0.86) in neuronal input resistance from 841 ± 111
MU in the absence to 743 ± 138 MU in the presence of leptin.
Plots of the voltage-current relations revealed extrapolated
reversal potentials for leptin-induced excitation around 35 mV
(Figure 5B). Taken together, these data suggest that leptin-
induced excitation is mediated via activation of one or more
nonselective cation conductances. In addition to these effects
onmembrane input conductance, leptin also inducedmodulation
of intrinsic subthreshold active conductance in a subpopulation
of DMH neurons. In DMH neurons, membrane depolarization
from negative holding potentials (< 65 mV) or depolarization
at the offset of the membrane response to hyperpolarization
frompotentials close to resting potential (45 to50mV) evoked
a transient depolarizing potential consistent with activation of a
low-threshold T-type calcium conductance. In the presence of
leptin, this potential was prolonged (Figure 5B), the half-time
to decay increasing from 132 ± 59 ms in the absence to 179 ±
61 ms in the presence of leptin. These data are consistent with
leptin modulating intrinsic active conductances in a subpopula-
tion of DMH neurons. In addition to these postsynaptic effects,
leptin induced an increase in spontaneous excitatory postsyn-
aptic potentials (EPSPs) in a subpopulation (n = 2) of DMH neu-
rons (Figure S4B). The mean frequency of spontaneous EPSPs
increased from 0.07 ± 0.02 Hz to 0.31 ± 0.11 Hz in the presence
of leptin. These EPSPs could be of sufficient magnitude to reach
threshold for firing, suggesting that indirect presynaptic effects
of leptin on DMH neurons can contribute to leptin-induced
increases in neuronal excitability.P and HR
riod with either leptin antibody or vehicle (IgG control). Student’s t test, n = 4–8.
ys of treatment and posttreatment of leptin antibody or vehicle (IgG control).
r antagonist (LRA). Two way ANOVA, Bonferroni post hoc, n = 4-6
ean and DIO mice baselines. t test paired (DIO baseline versus LRA), unpaired
aCSF or LRA. Two-way ANOVA, Bonferroni post hoc test, n = 4–6.
to the baselines of lean and DIO mice. t test paired (DIO baseline versus LRA),
ay ANOVA, Bonferroni post hoc, n = 4–6.
nemeasurements of lean and DIOmice. t test paired (DIO baseline versus LRA),
RA DIO mice. t test, n = 4–6.
Figure S2.
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Figure 4. The DMH Is Involved in Leptin-Mediated In-
creases in HR and BP
(A) Daily change in HR (BPM) from baseline in DIO mice treated in
the DMH with aCSF or a LRA. Two-way ANOVA, Bonferroni post
hoc test, n = 4.
(B) Total 24 hr HR (BPM) after 7 days of LRA treatment in the DMH
of DIO mice compared to lean and DIO mice at baseline. t test
paired (DIO baseline versus LRA), unpaired t test. n = 4–37.
(C) Daily change in SBP (mmHg) from baseline in DIO mice treated
in the DMHwith aCSF or a LRA. Two-way ANOVA, Bonferroni post
hoc test, n = 4.
(D) Total 24 hr SBP (mmHg) after 7 days of LRA treatment in the
DMHof DIOmice compared to lean and DIOmice at baseline. t test
paired (DIO baseline versus LRA), unpaired t test. n = 4–37.
(E) Daily change in DBP (mmHg) from baseline in DIO mice treated
in the DMHwith aCSF or a LRA. Two-way ANOVA, Bonferroni post
hoc test, n = 4.
(F) 24 hr DBP (mmHg) after 7 days of LRA treatment in the DMH of
DIO mice compared to lean and DIO mice at baseline. t test paired
(DIO baseline versus LRA), unpaired t test. n = 4–37.
(G) Percentage change in SBP (mmHg) of DIO mice, following
control (scrambled AAV) or leptin receptor knockdown AAV into the
DMH. Two-way ANOVA, Bonferroni post hoc test, n = 4–6.
(H) Quantitative analysis from day 31 onward of AAV scrambled
control-injected DIO mice and AAV LepR knockdown-treated DIO
mice. t test, n = 4–6.
(I) 24 hr circadian rhythm of SBP (mmHg) at baseline and then
following the seventh day of AAV Cre injection into the DMH of
LepR flox mice. Two-way ANOVA, Bonferroni post hoc test, n = 4.
(J) 24 hr circadian rhythm of heart rate (BPM) at baseline and then
following the seventh day of AAV Cre injection into the DMH
of LepR flox TB mice. Two-way ANOVA, Bonferroni post hoc test,
n = 4.
(K) 24 hr circadian rhythm of SBP (mmHg) at baseline and then
following the seventh day of AAV Cre injection into the DMH
of LepR flox TB mice. Two-way ANOVA, Bonferroni post hoc test,
n = 4.
Values represent mean ± SEM. *p < 0.05 and **p < 0.01. See also
Figure S3.
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Figure 5. Leptin Excites Leptin-Receptor-Expressing Neurons in the DMH
(A) Whole-cell patch-clamp electrophysiology in LepR-Cre-YFP mice; bath application of leptin (100 nM) induced an increase in spontaneous firing rate.
(B) Voltage-current relations from the cell shown in Figure S4A before and following exposure to leptin (100 nM). Note the transient rebound depolarization at the
offset of the response to hyperpolarizing current injection and its prolongation in the presence of leptin, illustrated belowwith responses to hyperpolarizing current
injection in control (black) and in the presence of leptin (red). Right, plot of data shown in (B); note the decreased slope of the voltage-current relations in the
presence of leptin (100 nM) (open triangles) compared to control (closed squares), indicating a decrease in neuronal input resistance and extrapolated reversal
potential around 35 mV, consistent activation of a nonselective cation conductance.
(C) Averaged 5 min (data collected every 10 s) heart rate (BPM) of DIO mice injected in the DMH with inhibitor chimeric ion channel virus (pSyn::Flex-rev-PSAM
L141F:GlyR-IRES-GFP) and treated i.p. with vehicle or PSEM (5 mg/kg). n = 5.
(D) Average (20–180 min) heart rate (BPM) over treatment period of DIO mice injected in the DMH with inhibitor chimeric ion channel virus with vehicle or PSEM.
Paired t test, n = 5.
(E) Averaged 5min (data collected every 10 s) SBP (mmHg) of DIOmice injected in the DMHwith inhibitor chimeric ion channel virus and treated i.p. with vehicle or
PSEM (5 mg/kg). Two-way ANOVA, Bonferroni post hoc test, n = 5.
(F) Average (20–180 min) SBP (mmHg) in DIO mice injected in the DMH with inhibitor chimeric ion channel virus in mice treated i.p. with Veh or pharmacologically
selective effector molecule (PSEM). Paired t test, n = 5.
(G) Averaged 5min (data collected every 10 s) DBP (mmHg) of DIOmice injected in theDMHwith inhibitor chimeric ion channel virus and treated i.p. with vehicle or
PSEM (5 mg/kg). Two-way ANOVA, Bonferroni post hoc test, n = 5.
(H) Average (20–180 min) DBP (mmHg) of DIO mice treated with chimeric ion channel virus and with Veh or PSEM. Paired t test, n = 5.
(I) Average daily HR (BPM) in DIO mice injected in the DMH with inhibitor chimeric ion channel virus treated i.p. with Veh or PSEM for 3 days. Paired t test, n = 5.
(J) Average daily SBP (mmHg) in DIO mice treated with inhibitor chimeric ion channel virus and with Veh or PSEM for 3 days. Paired t test, n = 5.
Values represent mean ± SEM. *p < 0.05. See also Figure S4.In Vivo Inhibition of LepR DMH-Expressing Neurons
Decreases BP
In vivo, the effects of directly altering the neuronal activity
of LepR-expressing DMH neurons were assessed using engi-
neered pharmacologically selective chimeric ion channels for
activating and silencing neuron activity (Magnus et al., 2011).
Briefly, this technology requires the injection of a virus, which
only infects and replicates in a Cre-dependent manner, intoCre-expressing mice. The virus drives the Cre-dependent ex-
pression of a modified ion channel, containing a PSAM element.
After injection (intraperitoneal injection), the otherwise inert
molecule PSEM binds to an ion channel that contains a PSAM
element, which opens the ion pore and allows ion flux across
the cell membrane, which depolarizes or hyperpolarizes virus-
infected, Cre-expressing neurons. Using male 20-week-old
chow-fed lean LepR-Cre-YFP transgenic mice (Leshan et al.,Cell 159, 1404–1416, December 4, 2014 ª2014 The Authors 1411
Figure 6. Blood Pressure Measurements in
Humans with Leptin and Leptin Receptor
Mutations
(A) Leptin-deficient children (n = 8) have signifi-
cantly lower SBP (mmHg) compared to age- and
weight-matched control subjects (n = 42).
(B) Leptin-receptor-deficient children (n = 12) have
significantly lower SBP (mmHg) compared to age-
and weight-matched control subjects (n = 48).
(C) Baseline pretreatment mean arterial pressure
(MAP) (mmHg) of leptin-deficient adult and control
subjects. n = 3.
(D) Change in MAP (mmHg) after 19 weeks of
weight loss treatment. n = 3.
Value represent mean ± SEM. Student’s t test.
*p < 0.05. See also Figure S5 and Table S1.2012), we investigated whether activation of DMH LepR-
expressing neurons could increase HR and BP. Lean LepR-
Cre-YFP mice were injected bilaterally with activator virus, an
engineered ionotropic serotonin receptor packaged in an
AAV2 (pSyn::Flex-rev-PSAM Y115F:5HT3 HC-IRES-GFP) into
the DMH. In lean mice 21 days after virus injection, twice daily
intraperitoneal (i.p.) administration of the receptor ligand
PSEM (i.p. 2X daily [5 mg/kg]) for 3 days significantly increased
HR and BP (p % 0.05; Figures S4D–S4F) compared to vehicle-
treated mice. In DIO LepR-Cre-YFP mice, an inhibitory virus, an
engineered ionotropic glycine receptor packaged into an AAV2
(AAV2: pSyn::Flex-rev-PSAM L141F:GlyR-IRES-GFP) was
administered bilaterally into the DMH. Compared to vehicle
treated mice, PSEM acutely decreased HR (Figures 5C and
5D) and SBP (Figures 5E and 5F), but no significant change in
DBP was observed (Figures 5G and 5H). Sub-chronic daily
treatment with PSEM reduced HR (by 72.6 ± 5.6 bpm), SBP
(by 6.1 ± 1.7 mmHg) and DBP over 3 days (Figures 5I, 5J, and
S4C), effects which were reversed once PSEM treatment
ceased. Treatment of mice with PSEM, prior to virus administra-
tion had no effect on HR or BP (Figures S4G and S4H). Cumu-
latively, these findings indicate that leptin signaling is required
for the changes in BP seen in DIO and that LepR expressing
neurons in the DMH are necessary and sufficient to, cause
these effects. These data also support the premise that the hy-
pertension induced by leptin in the DMH is due to leptin-
induced depolarization of DMH neurons.
Human Leptin and Leptin Receptor Mutations Are
Associated with Low Blood Pressure Despite Severe
Obesity
Homozygous complete loss-of-function mutations in the gene
encoding leptin (LEP) are associated with undetectable leptin
levels and severe early-onset obesity in humans (Montague
et al., 1997). We measured BP in the fasted rested state in eight1412 Cell 159, 1404–1416, December 4, 2014 ª2014 The Authorsleptin-deficient children and 42 equally
obese controls of the same age with
normal leptin levels for the degree of
obesity studied in the same conditions
(Table S1). SBP was significantly lower
in leptin-deficient children compared toage- and BMI-matched controls (Figure 6A; p < 0.05); there
was no difference in DBP. A statistically significant attenuation
of SBP was also seen in severely obese children who were ho-
mozygous for complete loss-of-function mutations in the LEPR
gene (n = 12) compared to 48 age- and BMI-matched controls
(Figure 6B; p < 0.05) (Table S1). There were no significant differ-
ences in resting HR between the groups (data not shown).
Administration of recombinant methionyl human leptin to individ-
uals with congenital leptin deficiency leads to significant weight
loss (Farooqi et al., 1999; Ozata et al., 1999). In a previously re-
ported experimental paradigm (Galgani et al., 2010), three lep-
tin-deficient adults were studied before and after treatment
with recombinant leptin for 19 weeks, which was sufficient to
cause 15.5 ± 0.5 kg weight loss. In parallel, three age- and
BMI-matched controls were studied before and after a diet
and exercise intervention, which achieved a comparable degree
of weight loss (14.8 ± 1.76 kg). The three adult leptin-deficient in-
dividuals were found to have normal BP despite severe obesity
(Figure 6C). Whereas the MAP of the obese control group
decreased as expected (Figure 6D), the BP of the leptin-deficient
adults did not change. No difference in HR was observed (Fig-
ure S5). Similarly, there was no statistically significant change
in BP after recombinant leptin administration to leptin-deficient
children (data not shown). These studies in rare individuals
completely lacking leptin or functioning LEPR support the asser-
tion that leptin is necessary for the increased BP associated with
obesity in humans.
DISCUSSION
Leptin Is the Peripheral Signal Linking Weight Gain to
Changes in Blood Pressure
Cumulatively, these studies demonstrate that leptin signaling
is necessary for obesity-induced increased BP. We have used
multiple convergent methods, including making lean mice
obese, by adding leptin systemically and by restoring LepR to
the DMH of LepR-deficient mice. In all these studies, BP
increased. Similarly, we have studied reduced leptin signaling
in leptin- and LepR-deficient mice, neutralized circulating leptin
with a systemic antibody, infused LepR antagonist ICV and
intra-DMH; used shRNA to knock down LepR expression; selec-
tively deleted LepR; and inhibited LepR-expressing neurons
in the DMH of obese hypertensive mice. In all of these experi-
ments, reducing leptin signaling reduced BP, even in the
presence of obesity. Clinical studies in severely obese humans
with two different forms of defective leptin signaling show
that these observations are relevant to human physiology and
pathophysiology.
Leptin in the DMH Regulates Cardiovascular Function in
the Absence of Effects on BW
Leptin can acutely increase HR, BP, and BAT, even in anesthe-
tized animals, presumably through activation of the SNS (Enriori
et al., 2011; Marsh et al., 2003). Intracerebroventricular (ICV)
leptin increases SNA to numerous organs, including the lumbar,
kidney, and BAT regions (Haynes et al., 1999). Central antago-
nism of LepR caused a reduction in BP and HR in DIO hyperten-
sive mice. Although early lesion studies confirm the importance
of the DMH for the control of energy homeostasis, little is known
about the neurochemical phenotype of the neurons present in
the DMH (Elmquist et al., 1999; Lee et al., 2012). The DMH ap-
pears to have a critical ability to control thermogenesis and
is involved in elevated BAT-mediated thermogenesis found in
obese mice (Enriori et al., 2011; Fan et al., 2005; Morrison
et al., 2008). In the studies conducted with antagonism or knock-
ing down of the LepR in DIO mice, we did not find significant
changes in FI or BW. These results suggest that the DMH
LepR-expressing neurons are not essential for leptin’s effects
on BW because the mice lost no additional weight when LepRs
were inactivated. Although lesion studies have previously
demonstrated a critical role of the DMH in the control of BW,
we have shown that long-term knockdown of the LepR does
not significantly affect BW, despite the significant reduction in
BP and previously reported increase in BAT temperature in
obesity (Elmquist et al., 1999; Enriori et al., 2011). Additionally,
acute activation or inhibition of LepR-expressing neurons did
not change FI or BW.
Leptin in Humans
Contrary to our expectations, we did not observe an increase in
BP with the administration of leptin to leptin-deficient patients.
There are a number of possible explanations. First, the magni-
tude of leptin’s effect on BP may be too small to be detected
given the sensitivity of the tools for measurement of BP in
humans and the small number of individuals studied. Notably,
despite weight loss with continued leptin administration, we
did not see a significant decrease in BP in these patients as
would be expected in more common forms of obesity. These
effects are comparable to the effects of leptin on total energy
expenditure (TEE), another phenotype mediated by sympathetic
tone.We have previously shown that, in contrast to weight loss in
obese controls where TEE decreases, TEE does not change with
leptin administration in leptin deficiency (Galgani et al., 2010).Whether leptin increases BP (to a small degree) or leptin-defi-
cient individuals respond differently to weight loss cannot be
deduced from our data. However, our results are in line with
the suggestion that the effect of leptin administration may be
to prevent the reduction in BP expected in congenitally leptin-
deficient individuals as they lose weight. In previous trials of
leptin in common obesity, no effects on BP were observed
(Heymsfield et al., 1999). Rosenbaum and Leibel have shown
that controlled 10%weight loss in an experimental setting is suf-
ficient to reduce leptin levels and is associated with decreased
SNA (Rosenbaum et al., 2005).
Could Leptin Be Acting Peripherally?
It is possible that leptin could be producing some of its cardio-
vascular effects by acting peripherally. LepR are expressed
throughout the brain, including the brainstem; additionally,
LepR are expressed on cardiac myocytes, the kidney, and
arteries, including the coronary arteries (Knudson et al., 2005;
Purdham et al., 2004; Serradeil-Le Gal et al., 1997). We treated
DIO mice peripherally with a leptin antibody and then in a sepa-
rate experiment, DIO mice were treated centrally with the LepR
antagonist, and in both experiments, similar responses were
observed. In mice lacking the LepR, re-expression of the LepR
in only the DMH caused a dramatic increase in BP and HR.
The opposite effects occurred when the leptin receptors were
deleted from only the DMH region in hypertensive mice. Thus,
although LepR expression in peripheral regions may play a
role, the results presented here clearly demonstrate a key role
for the DMH LepR-expressing neurons in mediating the changes
in BP in obesity.
Is Leptin Action in the DMH Mediated by the
Melanocortin System?
Experiments in rodents and humans support a role for melano-
cortin signaling in the regulation of BP. Central administration
of a-MSH increases BP and HR in wild-type mice, but not in
Mc4r/ mice, which maintain a normal BP despite severe
obesity (Kuo et al., 2003; Morgan et al., 2008; Tallam et al.,
2005). In humans, heterozygous loss-of-function mutations
in MC4R are associated with a reduced prevalence of hyper-
tension, low SBP, lower urinary noradrenaline excretion, and
reduced peripheral nerve SNA (Greenfield et al., 2009; Sayk
et al., 2010). Moreover, systemic administration of a centrally
active melanocortin receptor agonist acutely increased BP in
obese volunteers (Greenfield et al., 2009). As such, some of lep-
tin’s effects on BPmay bemediated by themelanocortin system.
However, there are some indications that, in obesity, the POMC
neurons in the ARH become nonresponsive to leptin (this has
been termed leptin resistance), and this may limit how much
the actions of leptin can be transduced by the POMC neurons
in the ARH (Enriori et al., 2007; Knight et al., 2010; Mu¨nzberg
et al., 2004). Previous research has implicated the POMC neu-
rons of the ARH in the regulation of obesity-induced hyperten-
sion via activation of the IKKb/NF-kB pathway (Purkayastha
et al., 2011; Zhang et al., 2008). How POMC neurons interact
with the DMH LepR-expressing neurons has not been ad-
dressed in these studies, but the DMHLepR-expressing neurons
do send direct efferent projections to ARH neurons (GautronCell 159, 1404–1416, December 4, 2014 ª2014 The Authors 1413
et al., 2010). It is possible that the LepR-expressing neurons in
the DMH express Mc4r or that the DMH LepR-expressing neu-
rons act through other neurons that express Mc4r (Liu et al.,
2003). The degree to which leptin’s effects on BP in obesity
are dependent upon intact melanocortin signaling remains to
be determined (do Carmo et al., 2011; Harlan et al., 2011).
DMH Neurons Regulate Autonomic Outflow to the Heart
and Peripheral Vasculature
DMH LepR-expressing neurons are known to project to
numerous brain regions, including the PVH (Elmquist et al.,
1998; Gautron et al., 2010). DMH neurons also project to other
nuclei, including the Raphe pallidus nucleus (RPa) and rostral
ventrolateral medualla (RVLM) (Cao and Morrison, 2003; Horiu-
chi et al., 2004; Simonds and Cowley, 2013). Microinjection of
leptin into the DMH of anesthetized rats can induce an acute
increase in HR and BP (Marsh et al., 2003). The DMH-RPa
connection has already been recognized to be important in the
regulation of BAT thermogenesis in response to leptin (Zhang
et al., 2011). The RVLM, however, appears to have a greater con-
trol over the regulation of BP, compared to regulation of thermo-
genesis and HR (Horiuchi et al., 2006; Morrison et al., 2008). The
neurochemical phenotype of the LepR-expressing neuron popu-
lations in the DMH is still debated (Lee et al., 2012). Further
studies will be necessary to characterize the DMH circuits that
contribute to leptin’s effects on blood pressure and to charac-
terize the mechanisms by which these neurons modulate sym-
pathetic outputs to the heart and peripheral blood vessels.
Why Leptin—What about Insulin?
Although results here strongly demonstrate the role of leptin in
contributing to elevated BP in obesity, a number of other hor-
mones that change in response to weight gain could contribute.
As expected, we found that, compared to lean mice, plasma in-
sulin was elevated in all obese models. Despite this increase in
plasma insulin, it was only DIO mice that exhibited significantly
elevated BP, and insulin levels were not correlated with HR
or BP, suggesting that insulin contributes little to the chronic
elevation of BP seen in obesity. Also, insulin sensitivity as
measured by hyperinsulinemic euglycemic clamps is compara-
ble in human MC4R deficiency versus obese controls despite
a lower BP and reduced urinary catecholamine excretion in
MC4R-deficient subjects (Greenfield et al., 2009). Therefore,
our data do not support a role for insulin in mediating obesity-
induced increases in BP.
In conclusion, these observations suggest that pharmacolog-
ical approaches based on the modulation of leptin’s effects on
specific subpopulations of neurons could represent a potentially
useful therapeutic strategy for the treatment of obesity-asso-
ciated hypertension and for the prevention of some obesity-
associated cardiovascular disease.
EXPERIMENTAL PROCEDURES
All animal procedures were approved by Monash University animal ethics
committee. All mice were housed in a controlled environment in which lights
were on a 12 hr light/12 hr dark cycle; temperature and humidity remained con-
stant. In experiments to examine the development of hypertension, 4-week-1414 Cell 159, 1404–1416, December 4, 2014 ª2014 The Authorsold male C57bl/6J mice were implanted with radiotelemetry probes (DSI,
USA, model TA11PA-C10). These mice were allowed 2 weeks recovery post-
surgery and, following baseline recordings, mice were spilt onto either chow
(4.8% of fat, mouse and rat rodent chow diet, Specialty Feeds, Glen Forrest,
Australia) or HFD (43% of fat, SF04-001, Specialty Feeds, Western Australia,
Australia) for 20 weeks (140 days) in which recordings were taken every 13
to 15 days. After 20 weeks (140 days), the HFD fed mice were swapped
onto a chow diet (4.8% of fat, SF04-001, Specialty Feeds, Western Australia,
Australia) for 4 weeks. In all other experiments, male C57Bl/6J, leptin-deficient
(ob/ob), LepR-deficient (db/db), LepR-deficient (LepRTB (Berglund et al.,
2012), LepR flox, and LepR-Cre-YFP mice (Leshan et al., 2012) were placed
on either a chow diet or HFD diet at 4 weeks of age and continuing for 20
consecutive weeks, after which mice were used for experiments. All mice
were on a C57Bl/6J background. In all experiments, the animals’ BW and FI
were monitored daily. Specific experimental procedures for radiotelemetry,
pharmacological studies, genetic manipulations, and electrophysiological
studies are detailed in the Supplemental Information.
Human Studies
All human studies were conducted according to the principles outlined in the
Declaration of Helsinki and after approval by local ethical committees. All indi-
viduals or their parents (for children) gave written informed consent. Systolic
and diastolic BPweremeasured in the rested, fasted state using wrist BPmon-
itors (OMRON Healthcare, Hamburg, Germany) in leptin-deficient (n = 8) and
leptin-receptor-deficient children (n = 12) (Farooqi et al., 2002, 2007). Control
subjects were recruited from the Genetics of Obesity Study (GOOS) cohort.
These control subjects had been tested for mutations in leptin, leptin receptor,
and MC4R. Control subjects were age and BMI matched to leptin-deficient
and leptin-receptor-deficient subjects (n = 42 and 48, respectively) (Wheeler
et al., 2013).
Adult Studies
Leptin-deficient adult patients received pretreatment testing at the Pennington
center, along with weight- and BP-matched control subjects. The leptin-defi-
cient patients then received a 3 month treatment of recombinant leptin (Leptin
[Amgen Inc., Thousand Oaks; Galgani et al., 2010]). Subjects were all provided
a nutritionally balancedmixed diet during this period. Subjects then returned to
the Pennington center for posttesting. Control subjects with ‘‘normal’’ leptin
levels were administered a low-calorie diet (Galgani et al., 2010) for 9–20weeks
to cause the same weight loss and also returned to the Pennington center for
posttesting. Mean ± SEM, t test, **p < 0.01. All subjects provided written
informed consent. The study design was approved by the ethics committee
of the Pennington Biomedical Research Center. Approval for leptin replace-
ment included UCLA IRB approval (April 9, 2001) and FDA approval (IND appli-
cation number 61690).
Statistics
Data are represented as mean ± SEM, and error bars also indicate SEM.
p values were calculated by either unpaired or paired two-tailed Student’s
t test, One-way ANOVA with Bonferroni post hoc test or two-way ANOVA
with Bonferroni post hoc test. *p < 0.05, **p < 0.01, and ***p < 0.001.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, five
figures, and one table and can be found with this article online at http://dx.
doi.org/10.1016/j.cell.2014.10.058.
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